# US 2017/0253606 A1 · A Rapamycin Derivative, and a Preparation Method, Pharmaceutical Composition and Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253606 A1
- Document ID: US20170253606A1
- Status: Published application
- Kind: A1
- Application number: 15/315,226
- Filed: 2015-06-03
- Published: 2017-09-07
- Earliest claimed: 2014-06-03
- Assignees: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
- Applicants: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
- Inventors: Wu ZHONG; Song LI; Shuang CAO; Ruiyuan CAO; Junhai XIAO; Xinbo ZHOU; Xingzhou LI
- Web page: https://patentgrep.com/patent/US20170253606A1

## CPC

- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61L 31/08: Materials for coatings
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 491/18: Bridged systems
- A61L 2300/426: Immunomodulating agents, i.e. cytokines, interleukins, interferons
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention pertains to the field of pharmaceutical chemicals, and relates to a rapamycin derivative of Formula I, and a preparation method, pharmaceutical composition and use thereof. The compounds of the present invention overcome the defects of rapamycin in terms of water solubility and metabolic properties, and some of the compounds have an in vitro anti-tumor activity superior to rapamycin, have less toxicity to normal cells than rapamycin, and have very good druggability.

## Claims

### Claim 1

A compound of Formula I, or a pharmaceutically acceptable salt or hydrate thereof:
wherein,
R1 and R2 are independently selected from H, A and B, and R1, R2 cannot be H simultaneously;
wherein, in Formula A or Formula B,
arrows refer to sites where A or B links to mother ring of Formula I;
n independently is 1, 2, 3, 4, 5, 6 or 7;
R4 is independently selected from fluorine, chlorine, bromine, iodine, nitro, and cyano;
X1, X2, X3, X4, Y1, Y2, Y3, Y4, and Y5 are independently selected from C, S, O, N and Se atoms;
X1˜X2, X2˜X3, X3˜X4, Y1˜Y2, Y2˜Y3, Y3˜Y4, Y4˜Y5 are independently single bond or double bond;
Z1, Z2, Z3, Z4, Z5, Z6, Z7, Z8, Z9 are independently selected from hydrogen atom, hydroxy, aldehyde group, carboxyl, amino, cyano, halogen, C1-C6 alkyl, C3-C10 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylthiol, C3-C10 cycloalkoxy, C1-C6 alkenyl, eneynylheterocyclic ring, heterocycloalkyl, substituted heterocycloalkyl, aromatic ring, aromatic heterocyclic ring, benzo-aromatic heterocyclic ring, wherein the C1-C6 alkyl, aromatic ring, aromatic heterocyclic ring, benzo-aromatic heterocyclic ring are not substituted or substituted with 1, 2, 3, 4 or 5 substituents independently selected from the following groups: —F, —Cl, —Br, —I, nitro, hydroxy, amino, cyano, C1-C6 alkylthiol, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl and C1-C6 alkoxy.

### Claim 2 (depends on 1)

The compound of Formula I, or a pharmaceutically acceptable salt or hydrate thereof according to claim 1, wherein:
Z1, Z2, Z3, Z4, Z5, Z6, Z7, Z8, Z9 are independently selected from hydrogen atom, hydroxy, aldehyde group, carboxyl, amino, cyano, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C1-C3 alkylthiol, C3-C6 cycloalkoxy and C1-C3 alkyl-enyl.

### Claim 3 (depends on 1)

The compound of Formula I, or a pharmaceutically acceptable salt or hydrate thereof according to claim 1, wherein in Formula A, N atom together with X1, X2, X3, X4 form a thiazole ring.

### Claim 4 (depends on 1)

The compound of Formula I, or a pharmaceutically acceptable salt or hydrate thereof according to claim 1, wherein:
R1 and R2 are independently selected from H, carbonylmethyl-(4-methyl-thiazole R4 salt-3-yl), carbonylmethyl-(4, 5-dimethyl-thiazole R4 salt-3-yl), carbonylmethyl-(pyridine R4 salt-1-yl), carbonylmethyl-(3-hydroxy-pyridine R4 salt-1-yl), carbonylmethyl-(3-methyl-pyridine R4 salt-1-yl) and carbonylmethyl-(4-methyl-pyridine R4 salt-1-yl), wherein R4 is independently selected from fluorine, chlorine, bromine, iodine, nitro and cyano; and R1, R2 cannot be H simultaneously.

### Claim 5 (depends on 1)

The compound of Formula I, or a pharmaceutically acceptable salt or hydrate thereof according to claim 1, wherein the compound is selected from the following compounds:
31,42-O-carbonylmethyl-(4-methyl-thiazole bromide salt-3-yl)-rapamycin,
42-O-carbonylmethyl-(4-methyl-thiazole bromide salt-3-yl)-rapamycin,
31-O-carbonylmethyl-(4-methyl-thiazole bromide salt-3-yl)-rapamycin,
31,42-O-carbonylmethyl-(4,5-dimethyl-thiazole bromide salt-3-yl)-rapamycin,
42-O-carbonylmethyl-(4,5-dimethyl-thiazole bromide salt-3-yl)-rapamycin,
31-O-carbonylmethyl-(4,5-dimethyl-thiazole bromide salt-3-yl)-rapamycin,
31,42-O-carbonylmethyl-(pyridine bromide salt-1-yl)-rapamycin,
31,42-O-carbonylmethyl-(3-hydroxy-pyridine bromide salt-1-yl)-rapamycin,
31,42-O-carbonylmethyl-(3-methyl-pyridine bromide salt-1-yl)-rapamycin,
42-O-carbonylmethyl-(pyridine bromide salt-1-yl)-rapamycin,
42-O-carbonylmethyl-(3-methyl-pyridine bromide salt-1-yl)-rapamycin,
42-O-carbonylmethyl-(3-hydroxy-pyridine bromide salt-1-yl)-rapamycin,
42-O-carbonylmethyl-(4-methyl-pyridine bromide salt-1-yl)-rapamycin,
31,42-O-carbonylmethyl-(4-methyl-pyridine bromide salt-1-yl)-rapamycin,
31-O-carbonylmethyl-(3-methyl-pyridine bromide salt-1-yl)-rapamycin,
31-O-carbonylmethyl-(pyridine bromide salt-1-yl)-rapamycin, and
31-O-carbonylmethyl-(4-methyl-pyridine bromide salt-1-yl)-rapamycin.

### Claim 6 (depends on 1)

A method for preparing the compound of Formula I according to claim 1, which comprises steps of any one of the following processes (1) to (3):
Process (1): Preparation of compounds of Formula I with position 31,42 bis-substituted
Process (2): Preparation of compounds of Formula I with position 42 mono-substituted
Process (3): Preparation of compounds of Formula I with position 31 mono-substituted
wherein in the above methods (1) to (3),
R3 is independently selected from F, Cl, Br and I;
the other symbols are independently as defined in claim 1.

### Claim 7 (depends on 6)

The method according to claim 6, wherein in the last reaction step of Process (1), Process (2) or Process (3), a reagent is added, and the reagent is independently selected from 5-membered heterocyclic compound, and 6-membered heterocyclic compound.

### Claim 8 (depends on 1)

A pharmaceutical composition, which comprises the compound or a pharmaceutically acceptable salt or hydrate thereof of claim 1.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

A coronary stent, comprising a drug coating comprising the compound or a pharmaceutically acceptable salt or hydrate thereof according to claim 1.

### Claim 11 (depends on 1)

A method for suppressing immune, inhibiting mTOR, inhibiting mTORC1, inhibiting PI3K-Akt-mTOR signal pathway, inhibiting T lymphocyte proliferation, combating tumors, promoting tumor cell apoptosis, allowing cell cycle arrest at G1, lowering arterial embolism, combating aging, combating Alzheimer's disease, preventing organ rejection, combating inflammation or combating bacteria in vivo or in vitro, comprising a step of administering to a subject or a cell in need thereof an effective amount of the compound or a pharmaceutically acceptable salt or hydrate thereof according to claim 1.

### Claim at position 12

-13. (canceled)

### Claim 14 (depends on 1)

A method for treatment and/or prophylaxis of kidney cancer, lymphoma, lung cancer, liver cancer, breast cancer, neuroendocrine cancer, uterine sarcoma or gastric cancer, comprising a step of administering to a subject in need thereof, an effective amount of the compound or a pharmaceutically acceptable salt or hydrate thereof according to claim 1.

### Claim 15 (depends on 1)

The compound of Formula I, or a pharmaceutically acceptable salt or hydrate thereof according to claim 1, wherein in Formula B, N atom together with Y1, Y2, Y3, Y4, Y5 form a pyridine ring.

### Claim 16 (depends on 1)

The compound of Formula I, or a pharmaceutically acceptable salt or hydrate thereof according to claim 1, wherein Z1, Z2, Z3, Z4, Z5, Z6, Z7, Z8, Z9 are independently selected from hydrogen atom, hydroxy, and methyl.

### Claim 17 (depends on 1)

The compound of Formula I, or a pharmaceutically acceptable salt or hydrate thereof according to claim 1, wherein R1 and R2 are independently selected from H, carbonylmethyl-(4-methyl-thiazole bromide salt-3-yl), carbonylmethyl-(4, 5-dimethyl-thiazole bromide salt-3-yl), carbonylmethyl-(pyridine bromide salt-1-yl), carbonylmethyl-(3-hydroxy-pyridine bromide salt-1-yl), carbonylmethyl-(3-methyl-pyridine bromide salt-1-yl) and carbonylmethyl-(4-methyl-pyridine bromide salt-1-yl), and R1, R2 are not H simultaneously.

### Claim 18 (depends on 7)

The method according to claim 7, wherein the reagent is independently selected from thiazole, pyridine, thiazole substituted with one or more C1-C6 alkyl, pyridine substituted with one or more C1-C6 alkyl, thiazole substituted with one or more halogen atoms, and pyridine substituted with one or more halogen atoms.

### Claim 19 (depends on 7)

The method according to claim 7, wherein the reagent is independently selected from 4-methylthiazole, 4,5-dimethylthiazole, pyridine, 3-hydroxypyridine, 3-methylpyridine and 4-methylpyridine.

### Claim 20 (depends on 8)

The pharmaceutical composition of claim 8 further comprising a pharmaceutically acceptable excipient.
